###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 11 15 11 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIP2</sup>
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: XY RGS QY. Performed the experiments: XY MA. Analyzed the data: XY RKMK. Contributed reagents/materials/analysis tools: RKMK FS KY LDM PT. Wrote the paper: PT.
###end p 1
###begin p 2
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 37 41 37 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIP2</sup>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 807 811 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 816 822 816 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 959 963 959 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 967 973 967 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1054 1060 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 602 607 <span type="species:ncbi:9606">human</span>
###xml 1183 1190 <span type="species:ncbi:9606">patient</span>
CDKN1C (encoding tumor suppressor p57KIP2) is a cyclin-dependent kinase (CDK) inhibitor whose family members are often transcriptionally downregulated in human cancer via promoter DNA methylation. In this study, we show that CDKN1C is repressed in breast cancer cells mainly through histone modifications. In particular, we show that CDKN1C is targeted by histone methyltransferase EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3), and can be strongly activated by inhibition of EZH2 in synergy with histone deacetylase inhibitor. Consistent with the overexpression of EZH2 in a variety of human cancers including breast cancer, CDKN1C in these cancers is downregulated, and breast tumors expressing low levels of CDKN1C are associated with a poor prognosis. We further show that assessing both EZH2 and CDKN1C expression levels as a measurement of EZH2 pathway activity provides a more predictive power of disease outcome than that achieved with EZH2 or CDKN1C alone. Taken together, our study reveals a novel epigenetic mechanism governing CDKN1C repression in breast cancer. Importantly, as a newly identified EZH2 target with prognostic value, it has implications in patient stratification for cancer therapeutic targeting EZH2-mediated gene repression.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 337 342 337 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4A</sup>
###xml 679 684 679 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4A</sup>
###xml 718 721 718 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bachman1">[1]</xref>
###xml 868 871 868 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Karnik1">[2]</xref>
###xml 873 876 873 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bracken1">[3]</xref>
###xml 878 881 878 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kotake1">[4]</xref>
###xml 244 249 <span type="species:ncbi:9606">human</span>
###xml 397 402 <span type="species:ncbi:9606">human</span>
Cyclin-dependent kinase inhibitors (CDKIs) are a large family of proteins that regulate cell cycle progression, cell proliferation and differentiation. CDKIs show widespread involvement in tumor suppression and are deregulated in many types of human cancers by genetic and epigenetic alterations. Loss of expression of CDKIs, such as p16INK4A, due to promoter DNA hypermethylation, is frequent in human cancer and the CDKIs downregulation is associated with aberrant cell proliferation and tumor growth. In addition to promoter DNA methylation, histone modifications also play a role in inactivation of the CDK inhibitors. It has been shown that H3K9 methylation can occur at p16INK4A independently of DNA methylation [1]. More recently, inactivation of the INK4A locus by other mechanisms such as Polycomb-associated histone H3K27 methylation have also been reported [2], [3], [4].
###end p 4
###begin p 5
###xml 257 260 257 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Jones1">[5]</xref>
###xml 397 400 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Marks1">[6]</xref>
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Cameron1">[7]</xref>
###xml 787 790 787 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kleer1">[8]</xref>
###xml 792 795 792 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bachmann1">[9]</xref>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Cao1">[10]</xref>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kirmizis1">[11]</xref>
###xml 930 934 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kuzmichev1">[12]</xref>
###xml 1076 1080 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Varambally1">[13]</xref>
###xml 1160 1164 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Vire1">[14]</xref>
###xml 1166 1170 1166 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kondo1">[15]</xref>
###xml 1172 1176 1172 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Jiang1">[16]</xref>
###xml 1178 1182 1178 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-GalYam1">[17]</xref>
###xml 1184 1188 1184 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-McGarvey1">[18]</xref>
###xml 1411 1415 1411 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Egger1">[19]</xref>
###xml 1417 1421 1417 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-McGarvey2">[20]</xref>
###xml 728 733 <span type="species:ncbi:9606">human</span>
Pharmacological reagents have been used to understand the regulatory components of gene silencing in cancer. DNA methylation inhibitor 5-Aza-2'-deoxycytidine (5-Aza-C) has been used extensively to restore the expression of genes silenced by DNA methylation [5], whereas histone deacetylase (HDAC) inhibitors such as Trichostatin A (TSA) can induce gene expression by reversing repressed chromatin [6]. These two classes of agents can also act in synergy for the reactivation of epigenetically silenced genes [7]. In addition to histone deacetylation, histone methylation also contributes to gene silencing. In particular, Polycomb protein EZH2 (Enhancer of Zeste 2) is a histone methyltransferase that is often overexpressed in human cancers and is associated with cancer aggressiveness [8], [9]. EZH2 specifically methylates lysine 27 of histone H3 (H3K27), a repressive chromatin mark associated with gene silencing [10], [11], [12] and often represses target genes associated with growth control. It has been shown that EZH2-mediated gene repression requires HDAC activity [13] and its functional relationship to DNA methylation is also of current interest [14], [15], [16], [17], [18]. Furthermore, recent studies indicate that inhibiting DNA methylation alone or even with the aid of HDAC inhibitors is insufficient to induce an euchromatic chromatin state due to the retention of repressive histone marks [19], [20]. These findings suggest that for a stable reversion of epigenetic silencing in cancer, a complete reversal from the malignant heterochromatin to a normal euchromatin is required.
###end p 5
###begin p 6
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 25 29 25 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIP2</sup>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Pateras1">[21]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Li1">[22]</xref>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 514 518 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Tan1">[23]</xref>
###xml 576 582 576 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 123 128 <span type="species:ncbi:9606">human</span>
CDK inhibitor CDKN1C (p57KIP2) has been previously reported to be inactivated via promoter DNA methylation in a variety of human cancers [21], [22]. In this study, we report that the CDKN1C is repressed in breast cancer by multiple epigenetic mechanisms. We demonstrate that the CDKN1C gene is the target of EZH2-mediaed trimethylation of histone H3 at lysine 27 (H3K27me3) that coordinates with histone deacetylation to suppress CDKN1C expression. Combined treatment of DZNep, an inhibitor of histone methylation [23], with HDAC inhibitor TSA causes a robust reactivation of CDKN1C expression. We also demonstrate the prognostic value of EZH2-mediated CDKN1C repression in breast cancer and suggest its clinical significance for EZH2-targeted cancer therapeutics.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
CDKN1C repression in breast cancer cells is associated with histone modifications independently of DNA methylation
###end title 8
###begin p 9
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Tan1">[23]</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Jiang1">[16]</xref>
###xml 562 568 562 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 715 721 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
We have previously reported that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanosin A (DZNep) is able to inhibit histone methylation and depletes the EZH2 complex and the associated H2K27 methylation [23] and combination of DZNep with HDAC inhibitor TSA resulted in robust activation of H3K27me3 target genes [16]. In an effort to comprehensively understand the epigenetic events in breast cancer, we performed gene expression analysis in various breast cancer cell lines treated with DZNep, TSA or Aza, alone or in various combinations. We found that CDKN1C can be strongly induced by a combination of DZNep and TSA treatment compared to a modest induction by Aza (see below). This finding suggests that CDKN1C expression in breast cancer is predominately regulated by histone modifications instead of DNA hypermethylation.
###end p 9
###begin p 10
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 419 428 419 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1A</xref>
###xml 560 569 560 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1B</xref>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Pateras1">[21]</xref>
###xml 899 908 899 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1B</xref>
###xml 1052 1061 1052 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1C</xref>
###xml 1079 1085 1079 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1171 1177 1171 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1353 1362 1353 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1D</xref>
###xml 1415 1424 1415 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1D</xref>
###xml 1474 1480 1474 1480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
To validate this finding, we first examined the relationship between the DNA methylation status of the CDKN1C promoter and the levels of CDKN1C expression in various breast cancer cell lines as well as the non-cancerous breast epithelial cell line (MCF10A). To this end, we have used methylation-specific PCR (MSP) to examine three regions flanking the entire CpG island surrounding the transcription start site (TSS) (Figure 1A). We found that the immediate promoter regions (M2 and M3) appeared to be unmethylated in all the breast cancer cell lines tested (Figure 1B), though the similar regions have been previously found to be methylated in lung cancer [21]. In a more distal region (M1) 500 bp upstream of the TSS, DNA was found to methylated in certain breast cancer cell lines, including BT-474 and MDA-MB-231, as well as in MCF10A cells, indicating this methylation is not cancer specific (Figure 1B). Bisulfite genomic sequencing results further confirmed the lack of methylation in M2 and M3 regions in SK-BR-3, BT-474 and MDA-MB-231 cells (Figure 1C). Examination of CDKN1C expression from our breast cancer cell lines gene expression database indicates that CDKN1C expression displayed varied levels of expression but in general was reduced in most of the breast cancer cell lines (except the MDA-MB-231 cells) as compared to MCF10A cells (Figure 1D). RT-PCR analysis further validated the array data (Figure 1D). Of important notice, the expression pattern of CDKN1C does not seem to correlate with the methylation status in these cell lines.
###end p 10
###begin title 11
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
DNA methylation status of CDKN1C promoter in breast cancer cells.
###end title 11
###begin p 12
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 486 492 486 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
(A) Schematic representation of CDKN1C locus. Vertical bars indicate the CpG sites. TSS, transcription start site. M1, M2 and M3 represent genomic regions for methylation specific PCR (MSP) analysis. (B) MSP analysis of genomic regions surrounding the TSS of CDKN1C. SFRP1 was used as a positive control of effective bisulfite conversation. (C) Bisulfite genomic DNA sequencing results of indicated regions in SK-BR-3, BT-474 and MDA-MB-231 cells. (D) Upper panel, expression values of CDKN1C in Illumina expression data of breast cancer cell lines. Lower panel, expression of CDKN1C in indicated cell lines are determined by RT-PCR.
###end p 12
###begin p 13
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 524 533 524 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g002">Figure 2A</xref>
###xml 651 657 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 830 836 830 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 838 847 838 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g002">Figure 2B</xref>
###xml 939 945 939 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1017 1023 1017 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1142 1148 1142 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1344 1350 1344 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1617 1621 1617 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Yu1">[24]</xref>
###xml 1623 1627 1623 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Zhao1">[25]</xref>
###xml 1629 1633 1629 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Barski1">[26]</xref>
###xml 1635 1639 1635 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Pan1">[27]</xref>
We next set out to determine whether histone modifications are responsible for CDKN1C repression in breast cancer. We used chromatin immunoprecipitation (ChIP) coupled with quantitative PCR to assess the following histone marks: the repressive chromatin marks H3K27me3, H3K9me3, H3K9me2, and H4K20me3, as well as activating H3K4me3 and acetylated histone (H3K9/14 ac) that are normally associated with gene activation. A series of PCR primer sets were designed to probe the 4 kb chromatin region surrounding the CDKN1C TSS (Figure 2A). We comprehensively characterized the chromatin state in SK-BR-3, BT-474, MDA-MB-231 and MCF10A cell lines in which CDKN1C is expressed at different levels. We detected an abundant H3K27me3 in a region approximately 300 bp downstream of the TSS in SK-BR-3 cells that express the lowest level of CDKN1C (Figure 2B). This was also observed to a lesser extend in BT-474 cells that express a modest level of CDKN1C, and at low rates in MDA-MB-231 and MCF10A cells that express abundant CDKN1C. Consistent with the enrichment of H3K27me3, we also detected a strong binding of H3K27 methyltransferase EZH2 to the CDKN1C promoter in SK-BR-3, to a lesser extend in BT-474 cells but not in MDA-MB-231 and MCF10A cells. Thus, levels of enrichment of EZH2 and H3K27me3 correlate very well (inversely) with the levels of CDKN1C expression across these diverse cell lines. This finding is consistent with the notion that EZH2 and the associated H3K27me3 enrichment are correlated with gene repression in cancer cells, and the majority of H3K27me3 is detected in the region downstream of the TSS [24], [25], [26], [27].
###end p 13
###begin title 14
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Histone modifications at CDKN1C locus in breast cancer cells.
###end title 14
###begin p 15
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 639 645 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
(A) Schematic representation of CDKN1C locus, TSS (transcription start site). Numbered bars indicate the genomic regions analyzed for histone modifications using Chromatin immunoprecipitation (ChIP) assay. (B) ChIP assay analysis of indicated histone marks and EZH2 binding at CDKN1C locus in SK-BR-3, BT-474 and MDA-MB-231 breast cancer cells, as well as none-cancerous epithelial breast MCF10A cells. The enrichments of examined histone marks in the indicated regions were examined by quantitative PCR relative to input DNA. Error bars were calculated as standard error (+/-s.d.). (C) Gene cluster showing the differential expression of CDKN1C and correlated genes in H3K27me3 positive and negative breast cancer samples. The data was obtained through analyzing a breast cancer microarray dataset in Oncomine database ().
###end p 15
###begin p 16
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 133 142 133 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g002">Figure 2B</xref>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bernstein1">[28]</xref>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Mikkelsen1">[29]</xref>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 744 753 744 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g002">Figure 2B</xref>
###xml 978 984 978 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1105 1111 1105 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
In addition, abundant H3K4me3 near the TSS was detected in all the four cell lines, irrespective of the levels of CDKN1C expression (Figure 2B). This suggests that CDKN1C is marked by both repressive and activating histone marks in SK-BR-3 and BT-474 cells; a bivalent chromatin state that is generally associated with gene repression [28], [29]. Higher abundance of acetylated H3 (H3K9/14ac) was detected in CDKN1C-expressing MCF10A, MDA-MB-231 and BT-474 cells but was less detectable in SK-BR3 cells that express a lowest level of CDKN1C, indicating a positive correlation of H3K9/14ac with CDKN1C expression in these cells. We also detected the presence of another repressive mark H3K9me2 in BT-474 cells but not in other three cell lines (Figure 2B). Taken together, these results indicate that the chromatin states reflecting the abundance of repressive H3K27me3; activating H3K4me3 and H3K9/14ac, as well as their combinatorial effects, correlate well with the levels of CDKN1C expression in these cells. Other repressive histone modifications such as H4K20me3 and H3K9me3 were not detected at the CDKN1C locus (data not shown).
###end p 16
###begin p 17
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 249 258 249 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g002">Figure 2C</xref>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT17</italic>
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT5</italic>
###xml 505 510 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LAMB3</italic>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Tan1">[23]</xref>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
To further determine the association of H3K27me3 with the level of CDKN1C expression in human breast tumors, we took the advantage of an independent microarray dataset of human breast tumors stained with H3K27me3 in Oncomine microarray database (). Figure 2C shows that breast tumors stained positive for H3K27me3 display a consistent downregulation of CDKN1C compared with those negative for H3K27me3. Of important note, genes exhibiting the similar expression patterns to CDKN1C include KRT17, KRT5 and LAMB3 that have been validated to be EZH2 target in our previous study [23]. Thus, the data from both clinical breast tumor samples and cancer cell lines all support that CDKN1C downregulation in breast cancer is associated with a higher level of H3K27me3.
###end p 17
###begin title 18
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Robust activation of CDKN1C expression by a combination treatment with DZNep and TSA
###end title 18
###begin p 19
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 606 612 606 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 780 789 780 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3A</xref>
###xml 816 822 816 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 916 922 916 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 954 963 954 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3A</xref>
###xml 1092 1098 1092 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1257 1263 1257 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1265 1274 1265 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3A</xref>
###xml 1382 1388 1382 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1572 1578 1572 1578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1606 1610 1606 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN</italic>
###xml 1744 1750 1744 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1D</italic>
###xml 1917 1926 1917 1926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3B</xref>
The different chromatin configurations at CDKN1C in SK-BR-3, BT-474 and MDA-MB-231 cells may predict differential response of CDKN1C expression to various epigenetic drug treatments. We next treated these breast cancer cell lines with DZNep, TSA, or Aza alone or in various combinations and performed quantitative RT-PCR to assess the changes of CDKN1C expression upon these treatments. To determine the specificity of the gene response, other CDKI family members were also included for the expression analysis. The results indicate that the combination of DZNep with TSA resulted in a robust induction of CDKN1C expression in SK-BR-3 cells, whereas the single drug treatment or other drug combinations, such as DZNep/Aza or TSA/Aza, did not give rise to such a strong induction (Figure 3A). As a marked contrast to CDKN1C, other CDKI family members did not respond to a similar extent, revealing the sensitivity of CDKN1C to this combination treatment (Figure 3A). Moreover, in BT-474 cells that display a lower abundance of H3K27me3, DZNep/TSA treatment only induced a 12-fold induction of CDKN1C, as opposed to a 70-fold induction in SKBR-3 cells. This response was much weaker in MDA-MB-231 cells and MCF10A cells that exhibit low levels of H3K27me3 in CDKN1C (Figure 3A). Taken together with the previous results, the data further support the conclusion that H3K27me3 level in CDKN1C is closely associated with its expression inversely. It also suggests that inhibition of H3K27me3 by DZNep alone is insufficient but requires TSA treatment for a full reactivation of CDKN1C. Lack of response of other CDKN family members to DZNep/TSA indicates the lack of similar chromatin state in these genes. Indeed, we found that other CDKIs, such as CDKN1D, were not marked by H3K27me3 in SK-BR-3 cells (data not shown). Finally, we confirmed the induction of CDKN1C protein expression in a similar manner by western blot (Figure 3B).
###end p 19
###begin title 20
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Changes of CDKN1C expression in response to DZNep, TSA, Aza and their combinations.
###end title 20
###begin p 21
###xml 173 177 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN</italic>
###xml 412 416 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIT1</italic>
(A) SK-BR-3, BT-474, MDA-MB-231 and MCF10A cells were treated with 5 microM DZNep (D), 100 nM TSA (T), and 5 uM 5-AzaC (A) along or in indicated combinations. Expression of CDKN members were analyzed by quantitative RT-PCR. Shown were the folds of induction relative to the untreated cells. (B) Western blot analysis of CDKN1C protein expression in SK-BR-3 and BT-474 cells. (C) RT-PCR results show no change of LIT1 expression upon indicated drug treatment. .
###end p 21
###begin p 22
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 145 153 145 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DMR-LIT1</italic>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Soejima1">[30]</xref>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 251 259 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DMR-LIT1</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIT1</italic>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIT1</italic>
###xml 403 412 403 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3C</xref>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 493 497 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIT1</italic>
CDKN1C is an imprinting gene, whose expression is also negatively regulated by an imprinted control region that contains a non-coding transcript DMR-LIT1[30]. To test the possibility that the induction of CDKN1C might arise from the downregulation of DMR-LIT1, we looked at the expression of LIT1 upon above drug treatment. The result shows that LIT1 expression is not changed upon DZNep/TSA treatment (Figure 3C), excluding the possibility that CDKN1C induction by DZNep/TSA is the result of LIT1 downregulation.
###end p 22
###begin title 23
Combination treatment with DZNep and TSA synergistically reverses histone modifications
###end title 23
###begin p 24
###xml 247 256 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g003">Figure 3A</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Tan1">[23]</xref>
###xml 609 618 609 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g004">Figure 4A</xref>
###xml 1117 1123 1117 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
We next examined the bulk histone modifications in cells treated with DZNep, TSA or both. Cellular histone was isolated from cell extracts and subjected to Western blot analysis using antibodies against relevant histone modifications. As shown in Figure 3A, DZNep treatment alone or in combination with TSA caused a diminished H3K27me3 in SK-BR3 and BT-474 cells, as anticipiated from our previous report [23]. A striking observation was the dramatic and synergistic increase in H3K9/14 acetylation in cells treated with the DZNep/TSA combination compared to cells treated with DZNep or TSA single treatment (Figure 4A). Although a decrease in H3K4me3 was also observed in cells treated with DZNep alone, the combination treatment seemed to cause a reverse of this decrease, leading to a level of H3K4me3 comparable to the untreated cells. Thus, the combination of DZNep and TSA induced a reversal of histone modifications by inhibiting H3K27me3 while enhancing acetated H3. This combinatorial effect on histone modification suggests a more permissive chromatin state overall, consistent with the robust induction of CDKN1C expression.
###end p 24
###begin title 25
Effects of DZNep/TSA combination on histone modifications.
###end title 25
###begin p 26
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
(A) Western blot results show the changes of histone modifications in response to the indicated treatment. Histone proteins were acid-extracted from indicated whole-cell lysates, and indicated histone modifications were analyzed with corresponding antibodies. Histone H3 was used as a loading control. (B) ChIP analysis detects the abundance of EZH2, H3K27me3, H3K4me3 and H3K9/14ac at CDKN1C locus before and after the DZNep/TSA combination treatment in SK-BR-3 cells. (C) SK-BR-3 cells were treated with negative control siRNA (NC) or EZH2 siRNA for 48 h, followed by TSA treatment for 24 h. Changes of CDKN1C, EZH2 and H3K27me3 protein levels were determined by Western blot analysis.
###end p 26
###begin p 27
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 248 257 248 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g004">Figure 4B</xref>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 666 672 666 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
We further performed ChIP analysis to determine the changes of chromatin following the above drug treatments. As expected, SK-BR-3 cells treated with DZNep/TSA showed an reduced EZH2 enrichment in CDKN1C, with a corresponding decrease in H3K27me3 (Figure 4B). Concomitantly, H3K9/14ac was enhanced after the combination treatment. Thus, taken together with the previous results from quantitative RT-PCR, we identified a strong correlation between the collective changes in histone modifications (H3K27me3 and H3K9/14 ac) and the expression levels of CDKN1C. This indicates that combination treatment with DZNep and TSA creates a permissive chromatin environment for CDKN1C expression through synergistically reversing associated chromatin marks.
###end p 27
###begin p 28
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g004">Figure 4C</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 437 446 437 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g004">Figure 4C</xref>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 741 747 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
To directly asses the role of EZH2 in CDKN1C expression, we used RNA interference to deplete the EZH2 expression. SK-BR-3 cells treated with small interfering RNA (siRNA) targeting EZH2 displayed a marked decrease in EZH2 expression, and a corresponding decrease in bulk H3K27me3 (Figure 4C). Depletion of EZH2, albeit insufficient to induce CDKN1C expression, resulted in a marked accumulation of CDKN1C protein in the presence of TSA (Figure 4C). This result is consistent with the previous pharmacology data and further indicates that effective CDKN1C induction requires inhibition of both EZH2 and histone deaceylation. It directly supports the model that histone deacetylation and EZH2-mediated histone methylation cooperate to repress CDKN1C expression.
###end p 28
###begin title 29
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Addition of Aza to DZNep/TSA combination further increases CDKN1C expression in BT-474 cells
###end title 29
###begin p 30
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 131 140 131 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g001">Figure 1B</xref>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 385 391 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 452 461 452 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g005">Figure 5A</xref>
###xml 536 542 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 684 690 684 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 885 894 885 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g005">Figure 5B</xref>
###xml 947 953 947 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
In BT-474 cells, the upstream region of CDKN1C promoter (M1) was detected to be hypermethylated compared to that in SK-BR-3 cells (Figure 1B). We next examined whether addition of Aza in these cells would further enhance the level of CDKN1C induction by DZNep/TSA. BT-474 and SK-BR-3 cells were thus treated with DZNep/TSA in the presence or absence of Aza for 72 h and the changes in CDKN1C expression were determined by quantitative RT-PCR analysis. Figure 5A shows the triple treatment in BT-474 cells induced a 27-fold induction of CDKN1C expression compared to a 12-fold induction by DZNep/TSA. By contrast, addition of Aza in SB-KR-3 cells did not further increase the level of CDKN1C which is already strongly induced by DZNep/TSA. However, MSP analysis revealed that the Aza treatment in BT-474 cells for up to 96 h did not in fact reduce the DNA methylation in the M1 region (Figure 5B), suggesting that the further enhanced induction of CDKN1C in BT-474 cells upon the triple combination treatment is not the result of DNA demethylation.
###end p 30
###begin title 31
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Addition of Aza to DZNep/TSA combination further enhances CDKN1C expression in BT-474 cells.
###end title 31
###begin p 32
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
(A) Changes of CDKN1C expression in BT-474 and SK-BR-3 cells after treatment with DZNep/TSA (D/T) or Aza/DZNep/TSA (D/T/A) were determined by quantitative RT-PCR. (B) MSP analysis of the methylation status of M1 region in BT-474 cells treated with Aza or DZNep/TSA/Aza for indicated times. (C) ChIP analysis showing the changes of H3K9me2, H3K27me3, and H3K9/14ac at CDKN1C locus in BT-474 cells untreated and treated with DZNep/TSA or DZNep/TSA/Aza.
###end p 32
###begin p 33
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Wozniak1">[31]</xref>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 517 526 517 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g005">Figure 5C</xref>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 768 774 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 806 812 806 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 945 951 945 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
It has been recently reported that Aza can act independently of its ability to inhibit DNA methylation to reactivate gene expression by removing H3K9me2 [31]. Since CDKN1C is marked by H3K9me2 in BT-474 cells, we next examined if H3K9me2 in CDKN1C, together with other histone marks, have changed after the above treatments. The results show that H3K9me2 level was markedly reduced in cells treated with the three-drug combination, compared with cells treated with DZNep/TSA, while H3K27me3 levels remained the same (Figure 5C). Thus, the further increase in CDKN1C expression upon treatment with the triple drug combination in BT-474 cells might be due to additional inhibition of H3K9me2. This is consistent with the fact that Aza treatment did not further increase CDKN1C expression in SK-BR-3 in which CDKN1C is not marked by H3K9m2. Taken together, we conclude that histone modifications play a predominate role in epigenetic repression of CDKN1C in breast cancer cells.
###end p 33
###begin title 34
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
EZH2-mediated CDKN1C repression predicts breast cancer clinical outcome
###end title 34
###begin p 35
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 359 368 359 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g006">Figure 6A</xref>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 176 181 <span type="species:ncbi:9606">human</span>
###xml 268 273 <span type="species:ncbi:9606">human</span>
###xml 450 455 <span type="species:ncbi:9606">human</span>
Given the involvement of EZH2 in CDKN1C repression, we took the advantage of Oncomine microarray database and asked whether their expression levels are reversely correlated in human cancer. The search results revealed that EZH2 is consistently upregulated in multiple human cancer types including breast cancer, while CDKN1C is downregulated in these tumors (Figure 6A). This data suggest that EZH2-mediated CDKN1C repression might operate widely in human cancers, indicating the potential broad application of pharmacological inhibition of EZH2 for reactivating CDKN1C for cancer treatment.
###end p 35
###begin title 36
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Levels of CDKN1C expression predict the clinical outcome of breast cancer patients.
###end title 36
###begin p 37
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 352 359 352 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 511 516 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DKN1C</italic>
###xml 578 582 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 753 758 753 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DKN1C</italic>
###xml 811 815 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 827 833 827 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 481 489 <span type="species:ncbi:9606">Patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
###xml 716 724 <span type="species:ncbi:9606">Patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
(A) Upregulation of EZH2 and downregulation of CDKN1C expression are shown in multiple cancer types with indicated P values by comparing the tumor (red) and the adjacent normal (blue) tissues. The data is extracted from Oncomine microarray database (). Breast cancer patients were ranked according to different levels of EZH2 or CDKN1C as described in Methods. (B) Kaplan-Meier survival plots of disease-free survival (DFS) from Stockholm cohort (Miller, et. al., GEO ID GSE3494). Patients with higher EZH2 or CDKN1C expression are highlighted in red, while patients with lower EZH2 or CDKN1C expression are highlighted in green. (C) Kaplan-Meier survival plots of disease-free survival (DFS) from Stockholm cohort. Patients with higher EZH2 but lower CDKN1C are highlighted in green, while patients with lower EZH2 but higher CDKN1C are highlighted in red.
###end p 37
###begin p 38
###xml 101 104 101 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kleer1">[8]</xref>
###xml 106 109 106 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bachmann1">[9]</xref>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 432 436 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Miller1">[32]</xref>
###xml 438 442 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Hall1">[33]</xref>
###xml 595 599 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 604 610 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 685 693 661 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005011.s001">Table S1</xref>
###xml 748 757 724 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g006">Figure 6B</xref>
###xml 817 818 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 834 835 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 903 907 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 920 926 896 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 967 971 943 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 992 998 968 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1069 1073 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN</italic>
###xml 1318 1322 1294 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 1333 1339 1309 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1387 1388 1363 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1449 1455 1425 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1457 1466 1433 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005011-g006">Figure 6C</xref>
###xml 1508 1514 1484 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1909 1915 1885 1891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
###xml 1120 1128 <span type="species:ncbi:9606">patients</span>
###xml 1413 1421 <span type="species:ncbi:9606">patients</span>
###xml 1752 1759 <span type="species:ncbi:9606">patient</span>
###xml 1873 1881 <span type="species:ncbi:9606">patients</span>
Enhanced EZH2 expression has been previously shown to correlate with poor prognosis of breast cancer [8], [9]. We next determined whether CDKN1C as an EZH2-repressed target is reversely associated with the disease outcome. To this end, we examined the publicly available microarray dataset from two breast cancer cohorts with annotated clinical outcome, Uppsala (approximately251 patients) and Stockholm (approximately159 patients) [32], [33]. The Cox-proportional hazards regression analysis of both disease free survival (DFS) and metastasis-free survival (DMFS) in both data sets showed that EZH2 and CDKN1C are consistently associated with the disease outcome in a reverse manner (Table S1). Specifically, as shown in the Kaplan-Meier plots of Figure 6B, significant poorer outcome in disease free survival (DFS; P = 0.004227 and P = 0.005694) were observed between Stockholm patients with a higher EZH2 and a lower CDKN1C, respectively. This indicates that both EZH2 and its target gene CDKN1C can be used to predict breast cancer outcome. In comparison, no other CDKN family genes could significantly separate the patients by survival (data not shown), consistent with the hypothesis that these genes might not be targeted by EZH2 in breast cancer. Furthermore, we show that breast cancer expressing both higher EZH2 and lower CDKN1C show a much poorer disease-free survival rate (P = 0.001046) compared to patients with lower EZH2 and higher CDKN1C (Figure 6C). Thus, the combination of both EZH2 and CDKN1C may be more predictive of breast cancer recurrence than either one alone. This result suggests that assessing both EZH2 and its target gene may be more accurate to measure the activity of EZH2 pathway. This data also has implications in patient stratification for potential clinical use of EZH2-inhibiting agents such as DZNep. We predict that breast cancer patients with higher EZH2 and lower CDKN1C might receive the greatest benefit from cancer therapeutic targeting of EZH2-mediated gene repression.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-McGarvey3">[34]</xref>
Our findings suggest that Polycomb protein EZH2-mediated H3K27me3 might be the key chromatin mark associated with the transcriptional repression of CDKN1C in breast cancer cells. It also indicates that EZH2 functions through cooperation with histone deacetylation for effective repression of its target genes. Lack of dominate effect of DNA methylation, together with RT-PCR analysis, indicate that CDKN1C expression in breast cancer is maintained at low or basal levels rather than completely silenced. Indeed, CDKN1C can be only modestly induced by Aza but strongly induced by DZNep/TSA that targets both EZH2-mediated histone methylation and deacetylation. This finding indicates that DZNep/TSA might preferentially target genes whose repression is associated with H3K27me3 but not those completely silenced by DNA methylation. This is consistent with a recent study showing that EZH2 functions to maintain the low expression of target genes that lack DNA methylation but is not required for maintaining gene silencing predominantly caused by DNA methylation [34].
###end p 40
###begin p 41
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Weber1">[35]</xref>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kondo2">[36]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Nguyen1">[37]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Ooi1">[38]</xref>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Bernstein1">[28]</xref>
###xml 728 732 728 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Azuara1">[39]</xref>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Barski1">[26]</xref>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Mikkelsen1">[29]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Widschwendter1">[40]</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Ohm1">[41]</xref>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Schlesinger1">[42]</xref>
###xml 1174 1178 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-GalYam1">[17]</xref>
###xml 1180 1184 1180 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Ohm1">[41]</xref>
###xml 1186 1190 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Ohm2">[43]</xref>
We show that CDKN1C carries both repressive (H3K27me3) and activating (H3K4me3) chromatin marks, revealing a "bivalent" chromatin state. Moreover, recent studies have shown that methylation of H3K4 is reversely associated with DNA methylation of gene promoters [35], [36], [37] and that DNMT only recognizes unmethylated H3K4 to induce DNA methylation [38]. Thus, the detection of a strong H3K4me3 in the CDKN1C promoter is consistent with the lack of DNA methylation in the vicinity of the CDKN1C promoter as we observed in breast cancer cells. A 'bivalent' chromatin mark (H3K27me3 and H3K4me3) has been originally described in embryonic stem (ES) cells that is generally associated with genes transcribed in low levels [28], [39]. Recent studies have also indicated its existence in differentiated cells [26], [29]. Many tumor suppressor genes carrying a bivalent chromatin mark in ES cells are subject to further DNA methylation for stable gene silencing in cancer cells [40], [41], [42]. It has been proposed that during this malignant process DNA methylation confers a concomitant loss of H3K4 methylation after a bivalent chromatin is converted to a monovalent state [17], [41], [43]. The retention of the bivalent domain without DNA methylation indicates that this epigenetic mechanism also exists in cancer cells, which might also contribute to the malignant transformation together with the well-characterized DNA methylation. This finding has obvious therapeutic implications. As described above, these bivalent genes that are lowly transcribed (not completely silenced) might be most susceptible to histone modifying compounds such as DZNep/TSA as illustrated in this study, but not to DNA demethylating agents. These genes might contain important tumor suppressors that have been overlooked historically. We therefore speculate that the above described epigenetic treatment might open a new avenue for cancer therapeutics that aim to target this aberrant epigenetic process that has been previously under-appreciated in cancer.
###end p 41
###begin p 42
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Vire1">[14]</xref>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 428 434 428 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Kondo1">[15]</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-GalYam1">[17]</xref>
###xml 767 773 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 902 908 902 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1067 1073 1067 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
Our comprehensive epigenetic analysis of these observations highlights the emerging concept that multiple epigenetic mechanisms collaborate to repress gene expression in cancer cells. Furthermore, our results indicate that DNA methylation and EZH2-H3K27me3 might not be mechanistically linked as previously suggested [14]. In fact, we did not detect methylated DNA in EZH2-H2K27me3 enriched region in CDKN1C. Conversely, in the CDKN1C promoter region that appears to be methylated (such as in BT-474 cells), no EZH2-H3K27me3 was detected. This finding is consistent with the recent genomic scale analysis showing that H3K27me3-mediated gene silencing and DNA methylation target different set of genes [15], [17]. Despite the presence of both epigenetic events in the CDKN1C locus in BT-474 cells, EZH2-H3K27me3 appears to be the predominate one that is in synergy with histone deacetylation to repress CDKN1C expression. Targeting EZH2-H3K27me3 by DZNep would presumably synergize with HDAC inhibitors and/or Aza to maximally restore the tumor suppressor function of CDKN1C.
###end p 42
###begin p 43
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Yu1">[24]</xref>
###xml 522 526 522 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 1216 1222 1216 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1266 1270 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 1311 1317 1311 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1460 1466 1460 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1016 1023 <span type="species:ncbi:9606">patient</span>
###xml 1151 1159 <span type="species:ncbi:9606">patients</span>
###xml 1336 1341 <span type="species:ncbi:9606">human</span>
Finally, we show that the downregulation of CDKN1C by EZH2 in breast cancer is associated with a poor disease outcome. Mechanistically, this finding is consistent with the previous knowledge that overexpression of EZH2 correlates with a poor breast cancer prognosis. Moreover, a recent report shows that Polycomb repression signature genes can predict clinical outcome of multiple solid tumors [24]. These findings thus suggest the utility of EZH2 target genes as prognostic marks. We further show that the combination of EZH2 and CDKN1C gives a better prediction of disease outcome that achieved through either gene alone. This might suggest that measuring both EZH2 and its target gene activity as the readout might be more accurate in predicting the activity of this silencing pathway. Indeed, our data suggest that EZH2 alone is insufficient but requires other factors such as HDAC to assure a full functionally in repression of certain genes. Therapeutically, this information may provide significant values in patient stratification for potential clinical use of EZH2 inhibitors as anti-cancer agents. Such agents may be particularly useful for patients with breast cancer harboring EZH2-mediaed repression of CDKN1C. Furthermore, we show that upregulation of EZH2 and the corresponding downregulation of CDKN1C occur in multiple human cancers. This may suggest that the pharmacological approach we have demonstrated for inhibiting EZH2 and reactivating CDKN1C might have broad application for cancer therapy.
###end p 43
###begin title 44
Methods
###end title 44
###begin title 45
Cells and drug treatment
###end title 45
###begin p 46
Cell lines used in this study were all obtained from the American Type Culture Collection (ATCC). Cells were maintained in appropriate medium conditions until harvested. For drug treatment, cells were treated with 5 microM DZNep (obtained from National Cancer Institute of USA) or 5 microM 5-aza-2'-deoxycytidine (5-AzaC; Sigma) for 72 h, and trichostatin A (TSA; Sigma) at 100 nM for 24 h. For 5-AzaC treatment, the medium was replaced with freshly added 5-AzaC for every 24 h. For co-treatment of cells with 5-DZNep and TSA, DZNep was added for 48 h, and then treated with TSA for additional 24 h.
###end p 46
###begin title 47
RNA interference
###end title 47
###begin p 48
###xml 127 153 127 153 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GACUCUGAAUGCAGUUGCU -3&#8242;</named-content>
The siRNA targeting EZH2 and non-targeting control were purchase from from 1st BASE Pte Led (Singapore) as following sequence: 5'-GACUCUGAAUGCAGUUGCU -3'. SK-BR-3 cells were transfected with 100 nM final concentration of siRNA duplexes using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
###end p 48
###begin title 49
Histone extraction and immunoblot analysis
###end title 49
###begin p 50
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Tan1">[23]</xref>
Whole cell extract was prepared as previously [23]. Histone proteins were acid extracted following Upstate protocol. Western blots were probed with the following antibodies: anti-H3K27me3 (07-449), anti-H3K9me3 (07-442), anti-H3K9/K14ac (06-599), anti-H3K4me3 (07-473), and anti-EZH2 (AC22) were purchased from Upstate. Anti-H3 (3H1) was from Cell Signaling and anti-EZH2 and anti-p57 were from Santa Cruz Biotechnology.
###end p 50
###begin title 51
Quantitative real-time PCR and RT-PCR
###end title 51
###begin p 52
###xml 460 468 460 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005011.s002">Table S2</xref>
Total RNA was isolated from cell lines using Trizol (Invitrogen) and purified with the RNAeasy Mini Kit (Qiagen). Reverse transcription was performed using an RNA Amplification kit (Ambion). Quantitative real-time PCR was performed on a PRISM 7900 Sequence Detection System (Applied Biosystems) using TaqMan probes (Applied Biosystems). Samples were normalized to the levels of GAPDH mRNA. For PCR 100 ng of cDNA was used and the primer sequences are shown in Table S2.
###end p 52
###begin title 53
DNA methylation analysis
###end title 53
###begin p 54
###xml 223 244 223 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005011.s002">Supplementary Table 2</xref>
The CpG island DNA methylation status was determined by PCR analysis after bisulfited modification (EZ DNA Methylation-Gold Kit, Zymo Research,) and followed by methylation-specific PCR (MSP). Primer sequences are shown in Supplementary Table 2.
###end p 54
###begin title 55
Chromatin Immunoprecipitation (ChIP) assays
###end title 55
###begin p 56
###xml 654 662 654 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005011.s002">Table S2</xref>
ChIP assay was performed as previously with a modified protocol that uses QIAquick PCR purification kit (Qiagen) to purify precipitated DNA. The immunoprecipitapted DNA was quantitated by real-time quantitative PCR using PRISM 7900 Sequence Detection System (Applied Biosystems). Primer sets are designed to amplify approximately 200 bp around the indicated region. The following antibodies were used in this study: anti-H3K27me3 (Upstate), anti-H3K9me3 (Abcam), anti-EZH2 (Upstate, anti-H3K9/K4ac (Upstate), anti-Histone H3(Abcam). Quantification of ChIP results was performed relative to the input amount. The sequences of the PCR primers are shown in Table S2.
###end p 56
###begin title 57
Data set and survival analysis
###end title 57
###begin p 58
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Miller1">[32]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005011-Hall1">[33]</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN</italic>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 672 678 672 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 712 716 712 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 721 727 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 824 828 824 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 833 839 833 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 960 964 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 980 984 980 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 997 1003 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 1115 1119 1115 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EZH2</italic>
###xml 1132 1138 1132 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1154 1160 1154 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
The breast cancer data set from Uppsala and Stockholm cohorts with relevant clinical information have been described previously [32], [33]. The expression of probes of each CDKN gene was averaged and transformed to z-score. The positive z-score was treated as higher expression and the negative z-score was treated lower expression. Using the survival event status and time information, we computed the survival association of expression status (high/low expression) using Cox-Proportional Hazards model implementation (coxph) available in R-library "survival". Kaplan-Meier survival analysis was used for the analysis of clinical outcome. For the combination of EZH2 and CDKN1C, the average expressions of both EZH2 and CDKN1C genes were separately transformed to z-score. The tumors with opposite signs of z-scores of the EZH2 and CDKN1C were included in the analysis and the tumors with same signs of z-scores were left out of the analysis. Tumors in which EZH2 up or positive EZH2 z-score and CDKN1C down or negative CDKN1C z-score were classified as class with label "0". Tumors in which EZH2 down or negative EZH2 z-score and CDKN1C up or positive CDKN1C z-score were classified as class with label "1". Similar survival analysis was carried out using cox proportional hazards model fitting and Kaplan-Meier plots.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin p 60
(0.02 MB XLS)
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin p 62
(0.03 MB XLS)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin title 64
References
###end title 64
###begin article-title 65
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.
###end article-title 65
###begin article-title 66
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
###end article-title 66
###begin article-title 67
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells.
###end article-title 67
###begin article-title 68
pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene.
###end article-title 68
###begin article-title 69
Cellular differentiation, cytidine analogs and DNA methylation.
###end article-title 69
###begin article-title 70
Histone deacetylase inhibitors.
###end article-title 70
###begin article-title 71
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
###end article-title 71
###begin article-title 72
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
###end article-title 72
###begin article-title 73
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
###end article-title 73
###begin article-title 74
Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
###end article-title 74
###begin article-title 75
###xml 13 18 <span type="species:ncbi:9606">human</span>
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
###end article-title 75
###begin article-title 76
###xml 53 58 <span type="species:ncbi:9606">human</span>
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein.
###end article-title 76
###begin article-title 77
The polycomb group protein EZH2 is involved in progression of prostate cancer.
###end article-title 77
###begin article-title 78
The Polycomb group protein EZH2 directly controls DNA methylation.
###end article-title 78
###begin article-title 79
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
###end article-title 79
###begin article-title 80
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.
###end article-title 80
###begin article-title 81
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.
###end article-title 81
###begin article-title 82
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells.
###end article-title 82
###begin article-title 83
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
###end article-title 83
###begin article-title 84
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state.
###end article-title 84
###begin article-title 85
Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
###end article-title 85
###begin article-title 86
Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.
###end article-title 86
###begin article-title 87
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
###end article-title 87
###begin article-title 88
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
###end article-title 88
###begin article-title 89
###xml 104 109 <span type="species:ncbi:9606">Human</span>
Whole-Genome Mapping of Histone H3 Lys4 and 27 Trimethylations Reveals Distinct Genomic Compartments in Human Embryonic Stem Cells.
###end article-title 89
###begin article-title 90
###xml 57 62 <span type="species:ncbi:9606">human</span>
High-resolution profiling of histone methylations in the human genome.
###end article-title 90
###begin article-title 91
###xml 74 79 <span type="species:ncbi:9606">Human</span>
Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27 Methylation in Human Embryonic Stem Cells.
###end article-title 91
###begin article-title 92
A bivalent chromatin structure marks key developmental genes in embryonic stem cells.
###end article-title 92
###begin article-title 93
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells.
###end article-title 93
###begin article-title 94
Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
###end article-title 94
###begin article-title 95
5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.
###end article-title 95
###begin article-title 96
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
###end article-title 96
###begin article-title 97
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study.
###end article-title 97
###begin article-title 98
DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2.
###end article-title 98
###begin article-title 99
###xml 93 98 <span type="species:ncbi:9606">human</span>
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome.
###end article-title 99
###begin article-title 100
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
###end article-title 100
###begin article-title 101
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.
###end article-title 101
###begin article-title 102
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA.
###end article-title 102
###begin article-title 103
Chromatin signatures of pluripotent cell lines.
###end article-title 103
###begin article-title 104
Epigenetic stem cell signature in cancer.
###end article-title 104
###begin article-title 105
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing.
###end article-title 105
###begin article-title 106
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer.
###end article-title 106
###begin article-title 107
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?
###end article-title 107
###begin p 108
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 108
###begin p 109
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by Agency for Science, Technology & Research (A* Star) of Singapore.(). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 109

